Novartis Aktie

110,80 EUR -3,76 EUR -3,28 %

11:39:24

XETRA

102,26 CHF -3,52 CHF -3,33 %

12:50:53

SWX

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.214,95 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

28.03.25BenzingaFDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool

28.03.25GlobeNewswireFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

28.03.25Dow JonesPress Release: FDA approves Novartis radioligand -2-

28.03.25Dow JonesPress Release: FDA approves Novartis radioligand therapy Pluvicto(R) for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant pro...

28.03.25ZacksHere's Why Novartis (NVS) is a Strong Value Stock

28.03.25ZacksAlcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock?

25.03.25ZacksAlcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval

25.03.25GlobeNewswireNovartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

25.03.25Dow JonesPress Release: Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta(R) in people with relapsing mult...

24.03.25BenzingaAlcon Eyes Surgical Edge With LENSAR Buyout: Details

21.03.25ZacksFDA Approves Novartis Drug for Rare Kidney Disease Treatment

21.03.25BenzingaFDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease

21.03.25PR NewswireNovartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

21.03.25GlobeNewswireNovartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

21.03.25Dow JonesPress Release: Novartis receives third FDA -2-

21.03.25Dow JonesPress Release: Novartis receives third FDA approval for oral Fabhalta(R) (iptacopan) -- the first and only treatment approved in C3 glomerulopathy (C3G)

20.03.25BenzingaNovartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders

20.03.25ZacksNovartis Reports Updated Positive Data From Phase III SMA Program

19.03.25BenzingaNovartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy

19.03.25GlobeNewswireNew Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

19.03.25Dow JonesPress Release: New Novartis Phase III data -2-

19.03.25Dow JonesPress Release: New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient popula...

13.03.25ZacksIs it the Right Time to Hold Alcon Stock in Your Portfolio Now?

12.03.25ZacksWhy Novartis (NVS) is a Top Value Stock for the Long-Term

07.03.25GlobeNewswireNovartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

03.03.25ZacksNovartis Gets CHMP Opinion for Label Expansion of Fabhalta

28.02.25ZacksAlcon Stock Gains From Innovation Despite Macroeconomic Troubles

28.02.25GlobeNewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25PR NewswireNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28.02.25GlobeNewswireNovartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

28.02.25Dow JonesPress Release: Novartis oral Fabhalta(R) -2-

28.02.25Dow JonesPress Release: Novartis oral Fabhalta(R) (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

26.02.25BenzingaCourt Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

26.02.25ZacksAlcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours

26.02.25ZacksAlcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say

25.02.25ZacksHere's Why Novartis (NVS) is a Strong Momentum Stock

20.02.25ZacksWall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings

20.02.25PR NewswireBMO Expands Canadian Depositary Receipt (CDR) Lineup with 10 New Listings from Europe and Japan

19.02.25PR NewswireCIBC introduces additional European Canadian Depositary Receipts ("CDRs")

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.